The Combined Effect of Acupuncture and Tanacetum parthenium on quality of life in women with headache: Randomised study

Abstract

Background

The aim of the present study was to investigate the efficacy and tolerability of acupuncture (AC), Tanacetum (TAN) or combined treatment on quality of life in women with chronic migraine (CM).

Methods

A total of 69 women volunteers were randomly divided into 3 groups: AC, acupuncture administered in 20 sessions over 10 weeks (n=22); TAN, at 150 mg/day (n=23); and AC+TAN (n=23). The primary outcome was Short-Form 36 (SF-36) quality of life assessment score. Secondary outcomes included the Migraine Disability Assessment (MIDAS) and visual analogue scale (VAS) score experienced after randomisation.

Results

AC+TAN was statistically significantly more effective than AC or TAN alone in overall health-related quality of life (SF-36; p<0.05), on MIDAS score (−35.1 (10.6) AC vs −24.8 (11.7) TAN vs −42.5 (9.8) AC+TAN; p<0.05) and in reducing the mean score of pain on VAS (−5.6 (2.4) AC vs −3.7 (2.1) TAN vs −6.4 (3.1) AC+TAN; p<0.05).

Conclusions

The present work shows an improvement of the quality of life and better analgesic effect of acupuncture combined with TAN treatment on migraine pain in women when compared with acupuncture or TAN alone.

Keywords

Acupuncture

References

Jena

, Witt

, Brinkhaus

, Acupuncture in patients with headache. Cephalalgia 2008;28:969.

Mathew

The prophylactic treatment of chronic daily headache. Headache 2006;46:1552–64.

Silberstein

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754–62.

Allais

, De Lorenzo

, Quirico

, Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine. Headache 2002;42:855–61.

Headache Classification Subcommittee of the International Headache Society. The International classification of headache disorders: 2nd edition. Cephalalgia 2004;24:9–160.

Olesen

, Bousser

, Diener

, New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742–6.

Olesen

, Tfelt-Hansen

, Ramadan

, The headaches. Philadelphia, PA: Lippincott Williams & Wilkins, 2005, 28–56.

, Fuh

, Chen

, Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 2001;21:980–6.

Bigal

, Serrano

, Reed

, Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559–66.

10.

Natoli

, Manack

, Dean

, Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599–609.

11.

Diener

, Limmroth

Medication-overuse headache: a worldwide problem. Lancet Neurol 2004;3:475–83.

12.

Lipton

, Bigal

, Diamond

, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–9.

13.

Juang

, Wang

, Fuh

, Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 2000;40:818–23.

14.

Dodick

. Clinical practice. Chronic daily headache. N Engl J Med 2006;354:158–65.

15.

Munakata

, Hazard

, Serrano

, Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2009;49:498–508.

16.

Gaul

, Eismann

, Schmidt

, Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia 2009;29:1069–78.

17.

Witt

, Reinhold

, Jena

, Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia 2008;28:334–45.

18.

Linde

, Allais

, Brinkhaus

, Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009;21:CD001218.

19.

Cheong

, Nardo

, Rutherford

, Acupuncture and herbal medicine in in vitro fertilisation: a review of the evidence for clinical practice. Hum Fertil 2010;13:3–12.

20.

Yeh-ching

, Jiahui

, Lay-cheng

, Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopaenic marrow diseases-a phase I/II clinical study. Complement Ther Clin Pract 2001;17:152–6.

21.

Zhu

, Proctor

, Bensoussan

, Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2008;16:CD005288.

22.

Pilkington

, Rampes

, Richardson

Complementary medicine for depression. Expert Rev Neurother 2006;6:1741–51.

23.

Peatfield

Drugs and the treatment of migraine. Trends Pharmacol Sci 1988;9:141–5.

24.

Magni

, Ruscica

, Dozio

, Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-α and NF-κB nuclear translocation in BV-2 Microglia. Phytother Res 2012;23. doi: 10.1002/ptr.3732.

25.

Murdoch

Feverfew for migraine prophylaxis. Can J Hospital Pharm 1989;42:209–10.

26.

De Weerdt

, Bootsma

HPR

, Hendriks

Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996;3:225–30.

27.

Banthorpe

, Brown

, Janes

, Parthenolide and other volatilies in the flowerheads of Tenacetum parthenium (L.) Schultz Bip. Flavour Fragr 1990;5:183–5.

28.

Awang

DVC

. Feverfew fever. A headache for consumer. Herbal Gram 1993;29:34–6.

29.

Hwang

, Fischer

, Jang

, Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810–18.

30.

Kang

, Chung

, Kim

. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappa B. Immunol Lett 2001;77:159–63.

31.

Pareek

, Suthar

, Rathore

, Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacogn Rev 2011;5:103–10.

32.

Palevitch

, Earon

, Carasso

Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytotherapy Res 1997;11:508–11.

33.

Murphy

, Heptinstall

, Mitchell

JRA

. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet, 1988:189–92.

34.

Vogler

, Pittler

, Ernst

Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998;18:704–8.

35.

Schiapparelli

, Allais

, Rolando

, Acupuncture in primary headache treatment. Neurol Sci 2011;32:S15–18.

36.

MacPherson

, White

, Cummings

, Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. J Altern Complement Med 2002;8:85–9.

37.

Ernst

, Pittler

. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000;3:509–14.

38.

Silberstein

. Migraine pathophysiology and its clinical implications. Cephalalgia 2004;24:2–7.

39.

Fanciullacci

, De Cesaris

Preventing chronicity of migraine. J Headache Pain 2005;6:331–3.

40.

Zijlstra

, van den Berg-de Lange

, Huygen

, Anti-inflammatory actions of acupuncture. Mediators Inflamm 2003;12:59–69.

41.

Humphrey

, Feniuk

, Perren

, Serotonin and migraine. Ann N Y Acad Sci 1990;600:587–600.

42.

Humphrey

. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991;238:S38–44.

43.

Lance

. 5-Hydroxytryptamine and its role in migraine. Eur Neurol 1991;31: 279–81.

44.

Feniuk

, Humphrey

, Perren

, Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol 1991;238:S57–61.

45.

John

, Goadsby

. Triptan signal transduction. In: Olesen

, Tfelt-Hansen

, Welch

KMA

. eds. The headaches. Chapp. 21-. 3rd edn. Pennsylvania: Lippincott Williams & Wilkins, 2006:203–11.

46.

Massiou

, Bousser

. Prophylactic drug treatment of migraine. Rev Neurol (Paris) 2005;161:681–4.

47.

Diener

, Limmroth

Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831–45.

48.

Silberstein

, Goadsby

. Migraine: preventive treatment. Cephalalgia 2002;22:491–512.

49.

Barsby

, Salan

, Knight

, Feverfew and vascular smooth muscle: extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med 1993;59:20–5.

50.

Béjar

Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol 1996;50:1–12.

51.

Mittra

, Datta

, Singh

, 5-Hydroxytryptamine-inhibiting property of feverfew: role of parthenolide content. Acta Pharmacol Sin 2000;21:1106–14.

52.

Weber

, O'Connor

, Hayataka

, Activity of parthenolide at 5HT2A receptors. J Nat Prod 1997;60:651–3.

53.

Shrivastava

, Pechadre

, John

. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig 2006;26:287–96.

54.

Macedo

, Baños

, Farré

Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain 2008;12:68–75.

55.

Hung

, Fuh

, Wang

. Validity, reliability and application of the taiwan version of the migraine disability assessment questionnaire. J Formos Med Assoc 2006;105:563–8.

56.

Mitchell

, Hewitt

, Jayakody

, Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J 2011;11:10:85.

57.

Molsberger

. Designing an acupuncture study: the nationwide, randomized, controlled, German acupuncture trials on migraine and tension-type headache. J Altern Complement Med 2006;12:237–45.